"Alkylating Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
| Descriptor ID |
D000477
|
| MeSH Number(s) |
D27.505.519.124 D27.888.569.035
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Alkylating Agents".
Below are MeSH descriptors whose meaning is more specific than "Alkylating Agents".
This graph shows the total number of publications written about "Alkylating Agents" by people in this website by year, and whether "Alkylating Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Alkylating Agents" by people in Profiles.
-
Toward personalized treatment in Waldenstr?m macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):365-370.
-
The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance. Curr Oncol Rep. 2007 Sep; 9(5):361-7.
-
A modified host-cell reactivation assay to measure repair of alkylating DNA damage for assessing risk of lung adenocarcinoma. Carcinogenesis. 2007 Jul; 28(7):1430-6.
-
Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transplant. 2006 Feb; 12(2):195-203.
-
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res. 2005 Nov 01; 11(21):7817-24.
-
Exocyclic DNA lesions stimulate DNA cleavage mediated by human topoisomerase II alpha in vitro and in cultured cells. Biochemistry. 2005 Mar 15; 44(10):3972-81.
-
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res. 2004 May 01; 10(9):2908-17.
-
A subgroup of microsatellite stable colorectal cancers has elevated mutation rates and different responses to alkylating and oxidising agents. Br J Cancer. 2004 Apr 19; 90(8):1666-71.
-
Overcoming methodological weakness in dose-intense alkylating agent studies through pharmacology. Clin Cancer Res. 2004 Jan 15; 10(2):413-4.
-
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002 Sep; 26(9):881-4.